Biogen Drops Alzheimer’s Drug Aduhelm, Ending a 17-year Chapter
Reuters) -Biogen will end a post-approval study of Alzheimer’s treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of obtaining standard regulatory approval. The drugmaker said on Wednesday it was concerned that by the time Aduhelm received a standard approval…
Read More
0
